跳至主要内容
临床试验/NCT00211159
NCT00211159已完成不适用

Omega-3 Fatty Acid Treatment of 174 Patients With Mild to Moderate Alzheimer's Disease (OmegAD): a Randomized Double-blind Trial

Karolinska University Hospital2 个研究点 分布在 1 个国家目标入组 204 人开始时间: 2000年12月1日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
204
试验地点
2
主要终点
Cognition measured according to ADAS-cog, MMSE scales

研究概览

简要总结

Memory loss and difficulties with thinking associated with Alzheimer's disease (AD) may be due to a deficiency in the brain of a fatty acid named DHA. The aim of this trial is to see if dietary supplementation with a preparation, rich in DHA, will halt cognitive impairment in AD patients

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double

入排标准

性别
All
接受健康志愿者

入选标准

  • Alzheimer's disease with MMSE 15-30, living in own homes, treated with stable dose of acetylcholine esterase inhibitor for >3 months and remaining on that treatment for the study period

排除标准

  • Already treated with omega-3 fatty acids, NSAIDs, warfarin, being an alcohol abuser, suffering from serious concomitant disease or not having a caregiver

结局指标

主要结局

Cognition measured according to ADAS-cog, MMSE scales

次要结局

  • Safety, tolerability, blood pressure
  • Dose-response studies in relation to APOE4 status, to body weight and to gender(2007-2018)
  • Gene expression(2007-2018)

研究者

发起方
Karolinska University Hospital
申办方类型
Other

研究点 (2)

Loading locations...

相似试验